Monitoring of minimal residual disease in the perspective of treatment of acute lymphoblastic leukemias in children

Treatment and diagnosis of acute lymphoblastic leukemias (ALL) in children have achieved much progress in the past years. Highly effective protocols for treatment of ALL have been developed, permitting to obtain remission in more than 90% of patients. Study of the level of minimal residual disease (MRD) permits to refer a patient to a certain group of risk, requiring a particular scheme of therapy and also to choose the optimal terms for bone marrow transplantation (BMT). Bone marrow (BM) samples of MRD-positive patients are very important for clarification of the mechanisms of tumour resistance to therapy. Introduction of new generation methods (high throughput sequencing, proteomics, bioinformatics) will permit to determine additional genetic and protein markers associated with higher levels of MRD, which in its turn might lead to creation of new effective markers and target therapeutic preparations.

минимальная остаточная болезнь (МОБ), острый лимфобластный лейкоз (ОЛЛ), полимерно-цепная реакция (ПЦР), проточная цитометрия, реаранжировки генов иммуноглобулинов _и Т-клеточного рецептора, minimal residual disease (MRD), acute lymphoblastic leukemia (ALL), polymerase chain reaction (PCR), flow cytometry, immunoglobulin and Т-cell receptor gene rearrangement